

In Re Application of:

Robert Jiang et al.

Confirmation No.: 8126

Serial No.: 10/759,555

Group Art Unit: 1624

Filing Date: January 16, 2004

Examiner: BERNHARDT EMILY B

Title: SUBSTITUTED HETEROCYCLIC COMPOUNDS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND CERTIFICATION UNDER 37 CFR § 1.97(e)


Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is a Su	pplemental Information Disclosure Statement submitted for the Examiner's
consideration. App	licants respectfully request that the Examiner review and make of record the
references identifie	d below.
The	references listed below are being submitted to the Office promptly after they
have become know	n to applicants and are being submitted prior to the final determination on
patentability by the	Office.
	references listed below were cited in an International (PCT) Search Report
dated April 26, 200	4, for the PCT application corresponding to the above-identified U.S. patent
application. A copy	of the Search Report, including an indication of the purported relevance of
the cited references	, is enclosed. Copies of the references are also submitted herewith, excluding
U.S. patents and/or	publications as the subject application was filed after June 30, 2003.
The	references identified below were disclosed in parent application Serial No. *.
As such, copies of t	he references are not included pursuant to the provisions of
37 CFR § 1.98(d).	

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

Atty Dkt No. 03-0185 Serial No. 10/759,555



F	OREIGN PATENT DOCUMENTS	
Document No.	Publication Date	Country
WO 02/32902	April 25, 2002	WIPO
EP 0 363 212	April 11, 1990	EP
EP 0 268 273	May 25, 1988	EP

NONPATENT DOCUMENTS	

This Supplemental Information Disclosure Statement is not intended as a representation that additional information material to the examination of this application does not exist or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Supplemental Information Disclosure Statement. If, for any reason, a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

As this Supplemental Information Disclosure Statement is being filed within three months of the date of the International Search Report (i.e, April 26, 2004), no fee is required at this time. If, for any reason, a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

The \$180.00 fee required by 37 CFR § 1.97(c) and set forth in 37 CFR § 1.17(p) accompanies this statement. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 CFR §§ 1.16, 1.17, and 1.21, or to credit any overpayment, to Deposit Account No. 50-1789.

The undersigned hereby certifies that:

Atty Dkt No. 03-0185 Serial No. 10/759,555

each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 CFR § 1.97(e)(1)).

or

that no item of information contained in this Information Disclosure Statement

that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement. (37 CFR § 1.97(e)(2)).

Respectfully submitted,

By

. Elin Hartrum

Registration No. 43,663

CV Therapeutics, Inc. 3172 Porter Drive Palo Alto, California 94304 Telephone: (650) 384-8755

Facsimile: (650) 475-0359

S:\LEGALCVT\Patent\Docs\03-0185\03-185-US\IDS - Supplemental for Search Report.DOC

Substitute	for form	n 1449A	/PTO

INFORMATION DISCLOSU STATEMENT BY APPEICA

	(use as many sneets as necessary)			
Sheet	1	of		

Complete if Known			
Application Number 10/759,555			
Filing Date	January 16, 2004		
First Named Inventor	Robert Jiang		
Art Unit	1624		
Examiner Name	Emily B. Bernhardt		
Attorney Docket Number	03-0185		

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
		US4723014	2-2-1988	Anderson et al.			
		US4820842	4-11-1989	Anderson et al.			
		US5405843	4-11-1995	Fukazawa et al.			
		US5112817	5-12-1992	Fukazawa et al.			
		US5204348	4-20-1993	Fukazawa et al.			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	Т
		WO 02/32902	April 25, 2002	WIPO	ĺ		
		EP 0 363 212	April 11, 1990	EP			
		EP 0 268 273	May 25, 1988	EP			

	OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т			
			┷			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.